Evidence map›Paper›PMID 40404867›Full record

Observational studyEuropean journal of nuclear medicine and molecular imaging2025

Detecting early cardiomyopathy in transthyretin variant carriers: reappraising the diagnostic value of Perugini grade 1 radiotracer uptake on bone scintigraphy.

H S A Tingen, M Berends, A Tubben, P van der Meer, R H J A Slart, J Bijzet, P A van der Zwaag, C Kimmich, C Knackstedt, F L H Muntinghe and 3 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

H S A TingenDepartment of Nuclear Medicine and Molecular Imaging, Groningen Amyloidosis Centre of Expertise, Groningen University, University Medical Centre Groningen, Groningen, The Netherlands.ORCID 0000-0002-8572-9428
M BerendsDepartment of Internal Medicine, Groningen Amyloidosis Centre of Expertise, Groningen University, University Medical Centre Groningen, Groningen, The Netherlands.
A TubbenDepartment of Cardiology, Groningen Amyloidosis Centre of Expertise, Groningen University, University Medical Centre Groningen, Groningen, The Netherlands.
P van der MeerDepartment of Cardiology, Groningen Amyloidosis Centre of Expertise, Groningen University, University Medical Centre Groningen, Groningen, The Netherlands.
R H J A SlartDepartment of Nuclear Medicine and Molecular Imaging, Groningen Amyloidosis Centre of Expertise, Groningen University, University Medical Centre Groningen, Groningen, The Netherlands.
J BijzetDepartment of Rheumatology & Clinical Immunology, Groningen Amyloidosis Centre of Expertise, Groningen University, University Medical Centre Groningen, Groningen, The Netherlands.
P A van der ZwaagDepartment of Clinical Genetics, Groningen Amyloidosis Centre of Expertise, Groningen University, University Medical Centre Groningen, Groningen, The Netherlands.
C KimmichDepartment of Oncology and Haematology, Klinikum Oldenburg, University Clinic, Oldenburg, Germany.
C KnackstedtDepartment of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands.
F L H MuntingheDepartment of Internal Medicine, Groningen Amyloidosis Centre of Expertise, Groningen University, University Medical Centre Groningen, Groningen, The Netherlands.
E J HouwerzijlDepartment of Internal Medicine, Groningen Amyloidosis Centre of Expertise, Groningen University, University Medical Centre Groningen, Groningen, The Netherlands.
B P C HazenbergDepartment of Rheumatology & Clinical Immunology, Groningen Amyloidosis Centre of Expertise, Groningen University, University Medical Centre Groningen, Groningen, The Netherlands.
H L A NienhuisDepartment of Internal Medicine, Groningen Amyloidosis Centre of Expertise, Groningen University, University Medical Centre Groningen, Groningen, The Netherlands. h.l.a.nienhuis@umcg.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo determine whether TTRv carriers with Perugini grade 1 cardiac radiotracer uptake on [

methodsThis retrospective observational study was conducted at the Groningen Amyloidosis Centre of Expertise between April 2012 and June 2023. TTRv carriers with Perugini grade 1 uptake on bone scintigraphy were followed until to June 2024. Data on symptoms, biomarkers, imaging, and biopsies were collected. A descriptive analysis was performed to evaluate whether carriers met the diagnostic criteria for ATTR-CM or 'probable ATTR-CM' at baseline and follow-up.

resultsOut of 178 TTRv carriers in screening, 12 carriers had Perugini grade 1 cardiac radiotracer uptake on bone scintigraphy. At baseline, 2 carriers met the diagnostic criteria for ATTR-CM and 3 carriers met the criteria for probable ATTR-CM. Of the 7 carriers without (probable) ATTR-CM at baseline, 3 carriers were diagnosed with ATTR-CM during follow-up and 1 carrier developed probable ATTR-CM during follow-up. Three carriers showed signs of cardiomyopathy during follow-up, but did not meet the criteria for (probable) ATTR-CM. One of these cases may have been false-positive due to hydroxychloroquine use.

conclusionOur findings suggest that Perugini grade 1 cardiac radiotracer uptake is an early marker of ATTR-CM in TTRv carriers, potentially enabling earlier diagnosis and intervention.

Indexed as

Amyloid Neuropathies, FamilialBone and BonesCardiomyopathiesHeterozygotePrealbuminAdultAgedBiological TransportFemaleHumansMaleMiddle AgedRadioactive TracersRadionuclide ImagingRetrospective StudiesPrealbuminRadioactive TracersATTR-CMATTRvDiagnosisEarly detectionScreening

Identifiers

PMID40404867
PMCPMC12589344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.